Promising antibody drug could save lives in rare, deadly lung disease

This study tests a drug called teclistamab for people with a severe, fast-worsening lung disease linked to anti-MDA5 antibodies. The disease is often fatal, with only about 25% of patients surviving 90 days without a lung transplant. Teclistamab is a bispecific antibody that helps the immune system target and destroy harmful cells. The goal is to see if it can improve survival and reduce the need for lung transplants. The trial will include 24 adults who have not responded to standard treatments.